Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The Intergroup Rhabdomyosarcoma Study-I. A final report.

H M Maurer1, M Beltangady, E A Gehan

  • 1Children's Medical Center, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298.

Cancer
|January 15, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Leukemia & lymphoma·2026
Same author

The effect of branded versus standardized e-cigarette packaging and device designs: an experimental study of youth interest in vaping products.

Public health·2024
Same author

Re: Some weighing of publication rates should be used to more fairly reflect the productivity of trainees. Re: re: Variation in UK Deanery publication rates in the British Journal of Oral and Maxillofacial Surgery: where are the current 'hot spots'?

The British journal of oral & maxillofacial surgery·2021
Same author

Variation in UK Deanery publication rates in the British Journal of Oral and Maxillofacial Surgery: where are the current 'hot spots'?

The British journal of oral & maxillofacial surgery·2020
Same author

Prevalence and pattern of energy drink intake among Australian adolescents.

Journal of human nutrition and dietetics : the official journal of the British Dietetic Association·2020
Same author

Setting up and maximising the usage of an Urgent Dental Care Centre in Blackpool. Sharing our experiences.

The British journal of oral & maxillofacial surgery·2020

This study analyzed 686 children with rhabdomyosarcoma or undifferentiated sarcoma. Key findings show no added benefit of radiation for localized disease or Adriamycin for advanced stages in specific treatment regimens.

Area of Science:

  • Pediatric Oncology
  • Medical Research
  • Clinical Trials

Background:

  • Rhabdomyosarcoma and undifferentiated sarcoma are rare pediatric cancers.
  • Treatment protocols for these sarcomas have evolved significantly.
  • The Intergroup Rhabdomyosarcoma Study-I (IRS-I) aimed to optimize treatment strategies.

Purpose of the Study:

  • To analyze the outcomes of 686 previously untreated pediatric patients with rhabdomyosarcoma or undifferentiated sarcoma.
  • To evaluate the efficacy of different treatment regimens, including chemotherapy and radiation, across various clinical groups.
  • To determine if specific therapeutic additions offered significant advantages in disease-free survival and overall survival.

Main Methods:

  • Analysis of data from 686 pediatric patients entered on the Intergroup Rhabdomyosarcoma Study-I (IRS-I).

Related Experiment Videos

  • Patients were stratified into four clinical groups based on disease extent (localized, regional, gross residual, metastatic).
  • Randomized treatment arms compared combinations of vincristine, dactinomycin, cyclophosphamide (VAC), Adriamycin, and radiation therapy.

    • Main Results:

    • For localized disease (Group I), adding radiation to VAC chemotherapy showed no significant difference in disease-free or overall survival.
    • For regional disease (Group II), adding cyclophosphamide to vincristine and dactinomycin plus radiation did not improve outcomes.
    • For advanced disease (Groups III and IV), Adriamycin did not improve complete remission or survival rates compared to VAC-based regimens; prognosis was significantly worse for metastatic disease (Group IV).

    Conclusions:

    • The study concluded that for the evaluated regimens, radiation is not beneficial for localized disease (Group I).
    • Cyclophosphamide did not offer an advantage for regional disease (Group II) in this context.
    • Adriamycin did not improve outcomes for advanced disease (Groups III and IV), and prognosis varied significantly by disease stage.